Leerink raised the firm’s price target on Danaher to $255 from $250 and keeps an Outperform rating on the shares. The firm sees Danaher as the leader in the attractive, recurring revenue market of bioprocess tools, while maintaining its position as a diversified consolidator in LST and Dx. Although Q4’s beat was driven by COVID testing, shares were up on a prudent 2024 guide of negative low single-digit organic growth and expected leverage when volumes recover, Leerink adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR:
- Danaher Corporation Reports Earnings: Did it Beat Estimate Forecasts?
- Danaher (NYSE:DHR) Drops on Dismal Q4 Numbers
- Danaher sees FY24 revenue down low-single digits, consensus $24.05B
- Danaher sees Q1 revenue down high-single digits, consensus $5.73B
- Danaher Reports Fourth Quarter and Full Year 2023 Results
